Day: March 27, 2024

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

Written by Customer Service on March 27, 2024. Posted in Public Companies.

SAN MATEO, Calif. and SINGAPORE, March 27, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024. ASLAN management will also be available for one-on-one meetings with investors on the day of the conference. Please register for the event via this link or contact your representative at H.C. Wainright to schedule a meeting. Company Presentation Information Format: Virtual presentation Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals Date: Thursday,...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Written by Customer Service on March 27, 2024. Posted in Public Companies.

– Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial – Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 – All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the year ended December 31, 2023 and provided an update on the completion of enrollment for its ongoing Phase 3 safety and efficacy study AEZS-130-P02 (the “DETECT-trial”) evaluating...

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

Written by Customer Service on March 27, 2024. Posted in Public Companies.

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.Presentation Details:Event: Cantor Virtual Muscular Dystrophy SymposiumDate: April 2, 2024Time: 3:10 PM ET The presentation webcast will be available on the Investors section of the Company’s website, and a replay will be accessible for at least 14 days. About Catalyst PharmaceuticalsWith...

Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Written by Customer Service on March 27, 2024. Posted in Public Companies.

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in CanadaRHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca.The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the launch of RHO Phyto Micro Drop 100, a 10% CBD (THC free), proprietary oral formulation in Canada. RHO Phyto Micro Drop 100, is designed to deliver enhanced absorption of cannabinoids through an inverted emulsion technology....

Alamos Gold Announces Friendly Acquisition of Argonaut Gold

Written by Customer Service on March 27, 2024. Posted in Mergers And Acquisitions.

Unlocking Value Through the Creation of One of Canada’s Largest and Lowest Cost Gold Mines TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — Alamos Gold Inc. (“Alamos”) (TSX:AGI; NYSE:AGI) and Argonaut Gold Inc. (“Argonaut”) (TSX:AR) are pleased to announce that they have entered into a definitive agreement (the “Agreement”) whereby Alamos will acquire all of the issued and outstanding shares of Argonaut pursuant to a court approved plan of arrangement (the “Transaction”). As part of the Transaction, Alamos will acquire Argonaut’s Magino mine, located adjacent to its Island Gold mine in Ontario, Canada. The integration of the two operations is expected to create one of the largest and lowest cost gold mines in Canada. Through the use of shared infrastructure, Alamos expects to unlock significant value with immediate and long-term synergies...

Evaxion Announces Business Update and Full Year 2023 Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completion of initial phases of vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). MSD revealed as pharma partner for the EVX-B3 bacterial vaccine development program. Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA. Closing of $15 million Public Offering on February 5, 2024, with participation of MSD GHI. MSD GHI is now the single largest shareholder in Evaxion, with ownership of around...

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Written by Customer Service on March 27, 2024. Posted in Earnings Releases And Operating Results.

Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV tested in >110 HNSCC patients Successful recent meeting with FDA provided clear guidance on trial design and regulatory pathway for pivotal randomized trial of triple combination in recurrent metastatic HPV-positive HNSCC Company to host conference call and webcast today at 8:00 AM ET PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology...

illumin Appoints Simon Cairns As Chief Executive Officer

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Tal Hayek to retire as illumin CEO to become Non-Executive Vice Chairman TORONTO, March 27, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced the appointment of Simon Cairns as Chief Executive Officer, effective April 15th. Mr. Cairns is a highly experienced executive with a successful track record driving growth and performance in technology, services, and SaaS platform companies. With over 24 years of strategic leadership, finance, marketing, operations, and business and corporate development experience, Mr. Cairns joins illumin at a pivotal point in the Company’s growth. Mr. Cairns most recently served as CEO of SPUD, western Canada’s largest...

R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report

Written by Customer Service on March 27, 2024. Posted in Public Companies.

Report highlights R1’s commitment to corporate responsibility and sustainability across the company’s global footprint MURRAY, Utah, March 27, 2024 (GLOBE NEWSWIRE) — R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, has released its 2023 Environmental, Social and Governance (ESG) report. The report details the company’s commitment to improving access to healthcare, bringing responsible global citizenship to life through its ESG program. R1 meets healthcare providers where they are on their revenue cycle journey and enables them to focus on what matters most – their patients, their employees and the health of their business. The company’s mission to make healthcare work better for all inspires R1’s efforts...

brooqLy Launches Operations in Sub-Saharan Africa with MrExportToAfrica

Written by Customer Service on March 27, 2024. Posted in Public Companies.

brooqLy is a technology company that has developed an innovative platform for consumers, brands, and retail shops to connect and interact through a Social Networking experiencebrooqLy Launches Operations in Sub-Saharan Africa with MrExportToAfricabrooqLy is a technology company that has developed an innovative platform for consumers, brands, and retail shops to connect and interact through a Social Networking experiencePALOS HILLS, Ill., March 27, 2024 (GLOBE NEWSWIRE) — brooqLy, Inc. (OTC: BRQL), a technology company, today announced a partnership, with MrExportToAfrica, an admirable international consulting firm headquartered in Ndola, Zambia. This partnership represents brooqLy’s commitment to delivering its platform across all continents, leveraging the expertise and local knowledge provided...

Day: March 27, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice